Results 41 to 50 of about 36,481 (278)
In Vivo Immunological Effects of CD73 Deficiency [PDF]
Cellular Physiology and Biochemistry, 2019 The extracellular ecto-5'-nucleotidase (CD73) is involved in the production of immunosuppressive adenosin (Ado), which can influence different immune cells through the specific adenosine receptors. The main aim of this work was to characterize immune cell populations as well as serum cytokine level in healthy CD73-deficient mice compared to healthy ...
Thomas Adam +6 more
openaire +3 more sources
The first CD73-instructed supramolecular hydrogel [PDF]
Journal of Colloid and Interface Science, 2015 Enzymatic supramolecular hydrogelation is a simple, controllable, and novel strategy for preparation of soft colloidal materials, which allows the integration of self-assembly with enzyme associated biological processes. The development of more enzymes involve in hydrogelation is a subject of developing useful soft colloids. In this work, an ectoenzyme,
Dongdong Wu +5 more
openaire +2 more sources
Targeting CD73 to augment cancer immunotherapy
Current Opinion in Pharmacology, 2020 CD73 (ecto-5'-nucleotidase) is a novel immunoinhibitory protein that plays a key role for tumor growth and metastasis. Its main function is to convert extracellular ATP to immunosuppressive adenosine in concert with CD39 in normal tissues to limit excessive immune response.
Meejeon Roh +4 more
openaire +2 more sources
Fluorescent Probes for Ecto-5′-nucleotidase (CD73) [PDF]
ACS Medicinal Chemistry Letters, 2020 Ecto-5'-nucleotidase (CD73) catalyzes the hydrolysis of AMP to anti-inflammatory, immunosuppressive adenosine. It is expressed on vascular endothelial, epithelial, and also numerous cancer cells where it strongly contributes to an immunosuppressive microenvironment.
Constanze C. Schmies +12 more
openaire +3 more sources
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases
OncoImmunology, 2017 The emerging role for CD73 in driving cancer growth and metastasis has presented opportunities to develop anti-CD73 monoclonal antibodies (mAbs) in the treatment of human cancers.
Dipti Vijayan +9 more
doaj +1 more source
CD73 is expressed by inflammatory Th17 cells in experimental autoimmune encephalomyelitis but does not limit differentiation or pathogenesis. [PDF]
PLoS ONE, 2017 CD73 works together with CD39 to convert extracellular ATP to immunoregulatory adenosine, thus inhibiting inflammation. TGFβ-mediated CD73 expression on 'regulatory' Th17 cells limits their ability to eradicate tumors, similar to the immunosuppressive ...
Gerard Hernandez-Mir, Mandy J McGeachy
doaj +1 more source
CD73 promotes tumor growth and metastasis [PDF]
OncoImmunology, 2012 Our recent data and that of others demonstrate that both tumor and host CD73-generated adenosine promote tumor growth and metastasis in a multifactorial manner. Results with small molecule inhibitors or monoclonal antibodies against CD73 in multiple tumor models suggest that CD73 is a previously unappreciated important target for effective cancer ...
openaire +2 more sources
OncoImmunology, 2017 CD39/CD73-adenosine pathway has been recently defined as an important tumor-induced immunosuppressive mechanism. We here documented a fraction of CD11b+CD33+ myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues from non-small ...
Jieyao Li +21 more
doaj +1 more source
Journal of Hematology & Oncology, 2020 Background Aberrant AKT activation contributes to cancer stem cell (CSC) traits in hepatocellular carcinoma (HCC). We previously reported that CD73 activated AKT signaling via the Rap1/P110β cascade.
Xiao-Lu Ma +6 more
doaj +1 more source
In vitro study of the role of CD73 receptor and S100b protein in skin inflammation.
, 2023 reservedÈ noto in letteratura che durante un’infiammazione cutanea si abbia un aumento dell’espressione di CD73 con un abbassamento delle difese immunitarie e un maggiore rilascio di proteina S100b, che per questa ragione è sfruttata come biomarker ...
NICOLETTI, MATTEO GENNARO
core